Cargando…

Identification of new prognostic biomarkers for Stage III metastatic melanoma patients

Accurately predicting disease outcome among patients bearing Stage III metastatic melanoma is complex. However, current advances in personalized medicine call for ever more precise prognostic assessments, as these have a significant impact not only on the design and analysis of clinical trials, but...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kakavand, Hojabr, Scolyer, Richard A, Thompson, John F, Mann, Graham J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2013
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3820811/ https://www.ncbi.nlm.nih.gov/pubmed/24228228 http://dx.doi.org/10.4161/onci.25564

Ejemplares similares

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
por: Wilmott, James S., et al.
Publicado: (2012)

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
por: Cooper, Zachary A., et al.
Publicado: (2013)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
por: Cooper, Zachary A, et al.
Publicado: (2014)

Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy
por: Liikanen, Ilkka, et al.
Publicado: (2015)

New strategies for melanoma immunotherapy: How to overcome immunosuppression in the tumor microenvironment
por: Umansky, Viktor
Publicado: (2012)

“Suffocating” tumors by blocking adaptation to hypoxia: a new headway in melanoma immunotherapy
por: Janji, Bassam, et al.
Publicado: (2021)

Immunity to live: an immunopathoscore using the consensus Immunoscore to best define the risk of recurrence and death in stage IV metastatic patients
por: Baldin, Pamela, et al.
Publicado: (2020)

Tumor infiltration by chemokine receptor 7 (CCR7)(+) T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer
por: Correale, Pierpaolo, et al.
Publicado: (2012)

Melanoma immunoediting by NK cells
por: Balsamo, Mirna, et al.
Publicado: (2012)

Melanoma metastases caught in the AKT
por: Kircher, David A., et al.
Publicado: (2016)

Barrett's esophagus stages: their correlation with SBS17-associated DNA mutations and the identification of histological marker genes
por: Busslinger, Georg A.
Publicado: (2022)

Monocytic myeloid-derived suppressor cells in advanced melanoma patients: Indirect impact on prognosis through inhibition of tumor-specific T-cell responses?
por: Martens, Alexander, et al.
Publicado: (2014)

Adoptive immunotherapy: New assay for the identification of T cells with optimal avidity
por: Weissbrich, Bianca, et al.
Publicado: (2013)

CD8(+) T lymphocytes infiltrating breast cancer: A promising new prognostic marker?
por: Mahmoud, Sahar, et al.
Publicado: (2012)

BRAF-targeted therapy and immune responses to melanoma
por: Ngiow, Shin Foong, et al.
Publicado: (2013)

How melanoma cells inactivate NK cells
por: Pietra, Gabriella, et al.
Publicado: (2012)

Disseminating melanoma cells surf on calcium waves
por: Sun, Jianwei, et al.
Publicado: (2015)

Is there a future for adoptive cell transfer in melanoma patients?
por: Besser, Michal J
Publicado: (2013)

The antigen specific composition of melanoma tumor infiltrating lymphocytes?
por: Hadrup, Sine Reker
Publicado: (2012)

Lymphoid neogenesis in melanoma: What does it tell us?
por: van Baren, Nicolas, et al.
Publicado: (2013)

Engineering hematopoietic stem cells to create melanoma specific CTL
por: Vatakis, Dimitrios
Publicado: (2012)

Forging a link between oncogenic signaling and immunosuppression in melanoma
por: Khalili, Jahan S., et al.
Publicado: (2013)

Neuropilin 1 guides regulatory T cells into VEGF-producing melanoma
por: Hansen, Wiebke
Publicado: (2013)

NRAS-driven melanoma: A RAF can hide another
por: Druillennec, Sabine, et al.
Publicado: (2017)

Stress-induced metastatic niches in breast cancer
por: Oskarsson, Thordur
Publicado: (2020)

Multiverse of immune microenvironment in metastatic colorectal cancer
por: Van den Eynde, Marc, et al.
Publicado: (2020)

Immune response markers in sentinel nodes may predict melanoma progression
por: Rodolfo, Monica, et al.
Publicado: (2014)

Ipilimumab in a Phase II trial of melanoma patients with brain metastases
por: Margolin, Kim
Publicado: (2012)

Enhancing anti-melanoma immunity by electrochemotherapy and in vivo dendritic-cell activation
por: Gerlini, Gianni, et al.
Publicado: (2012)

Melanoma hijacks plasmacytoid dendritic cells to promote its own progression
por: Aspord, Caroline, et al.
Publicado: (2014)

Counteracting oxidative phosphorylation-mediated resistance of melanomas to MAPK pathway inhibition
por: McQuade, Jennifer L, et al.
Publicado: (2015)

Hypoxia-driven immunosuppression contributes to the pre-metastatic niche
por: Sceneay, Jaclyn, et al.
Publicado: (2013)

Tumor stiffness extends its grip on the metastatic microenvironment
por: Reid, Steven E., et al.
Publicado: (2017)

Identification of human tissue cross-presenting dendritic cells: A new target for cancer vaccines
por: Haniffa, Muzlifah, et al.
Publicado: (2013)

Immunotargeting of tumor subpopulations in melanoma patients: A paradigm shift in therapy approaches
por: Maurer, Margarita, et al.
Publicado: (2012)

A path from melanocyte stem cells to cutaneous melanoma illuminated by UVB
por: Moon, Hyeongsun, et al.
Publicado: (2018)

PSPC1 potentiates TGF-β-dependent metastatic dissemination
por: Yeh, Hsi-Wen, et al.
Publicado: (2018)

Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody
por: Choi, Bryan D, et al.
Publicado: (2013)

Connecting androgen receptor signaling and the DNA damage response: Development of new therapies for advanced prostate cancer
por: Thompson, Timothy C., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vq0b3nhr9d2ch6jdd3klabhdp7